Advertisement

Director of Canada’s drug price regulator resigns same week as colleague steps down

Click to play video: 'Global National: Feb. 23'
Global National: Feb. 23
Fears are growing China could supply Russia with weapons to bolster its faltering invasion of Ukraine, as Chinese President Xi Jinping prepares to unveil his own “peace plan,” signalling his government's stance on the war. Ukrainian President Volodymyr Zelenskyy's plea to meet with Xi, and NATO's warning to Beijing. The horrific death toll from a year of Russia's war has sadly made funerals and burials a daily ritual, testing the strength and resilience of the Ukrainian people. Jeff Semple reports from Lviv with the story of one of the many soldiers who made the ultimate sacrifice, and the grief of loved ones left behind. A record number of people died from police-related incidents in Canada in 2022, according to researchers from the Tracking (In)Justice data and transparency project. The study also found persistent racial disparities. How calls for policing reform were amplified following the May 2020 death of George Floyd in Minneapolis, but in Canada, the situation only worsened. Plus, Google is blocking content from certain news sites for some Canadians, in what the tech titan calls a “test run” of its response to Bill C-18, also known as the Online News Act. The reaction to Google's move, how much money is at stake, and how long the test could last – Feb 23, 2023

The executive director of Canada’s drug pricing regulator is stepping down — just days after another member resigned because of concerns that the federal government was undermining the independent body’s work.

Douglas Clark, with the Patented Medicine Prices Review Board, announced Friday he would be leaving his post after almost a decade with the regulator that oversees the prices of medicines sold in Canada.

A day earlier, Matthew Herder, a professor of health law at Dalhousie University, announced he had resigned from the board, accusing the federal government of failing to implement critically important reforms that would lower the cost of medication.

“The government has fundamentally undermined the board’s independence and credibility,” Herder said in his resignation letter addressed to federal Health Minister Jean-Yves Duclos. Herder said he no longer believed it was possible to serve the public good in his role, which he had held since 2018.

Story continues below advertisement

Herder responded Friday on social media to news of Clark’s resignation, calling it an “an immense, irreplaceable loss.”

Federal NDP Health Critic Don Davies is calling for an investigation into Duclos’ alleged involvement in delaying drug reforms that would save Canadians money. Davies said in a statement Friday that for a minister to interfere in an independent regulator’s mandate is “highly questionable” and that prioritizing drug industry profits “over the welfare of Canadian patients is completely unacceptable.”

The latest health and medical news emailed to you every Sunday.

Clark has agreed to remain with the board as a special adviser for an unspecified amount of time, and the board said work to appoint Clark’s successor would be launched soon.

“People may come and go but the commitment of staff at the (regulator) to the very highest ideals of public service is unwavering and will endure,” Clark said in a statement.

Story continues below advertisement

The Patented Medicine Prices Review Board declined to comment, and Health Canada did not immediately respond to questions.

This report by The Canadian Press was first published Feb. 24, 2023.

Sponsored content

AdChoices